Threshold Pharmaceuticals Inc.

Threshold Pharmaceuticals, Inc., a development stage company, focuses on the discovery and development of drugs for the microenvironment of solid tumors and the bone marrows of hematologic malignancies as novel treatments for patients living with cancer. Its clinical development products include TH-302, a novel drug candidate, which is in Phase I, Phase II, and Phase III clinical trials for the severe hypoxic regions present in various solid tumors and hematologic malignancies.

Ticker:
THLD
Exchange:
NASDAQ (See More NASDAQ Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?